ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings exhibits a positive outlook as evidenced by its recent share gains in the global reconstructive market, which grew at 6% year-over-year in 4Q25, notably with the company's market share rising by 20 basis points to 32.9%. The firm demonstrated strong performance in its knee and hip segments, with knee sales reaching $911 million and hip sales at $555 million, both surpassing consensus estimates and reflecting year-over-year growth improvements. Additionally, the company's operational margin expansion, increasing from 28.6% reported for FY24, further underscores its financial health and robust performance in a competitive landscape.

Zimmer Biomet Holdings has encountered a consistent decline in organic revenue growth over the last eight quarters, a trend that is projected to persist through 2026, indicating potential challenges in sustaining its market position. The underperformance of Paragon 28, combined with a lack of significant contributions from new product launches in FY26, has led to lowered revenue expectations, further constraining growth potential. Additionally, operating margins have contracted by 170 basis points year-over-year due to increased selling, general, and administrative expenses, which, coupled with risks related to market conditions and pricing, reinforces a negative outlook for the firm's stock.